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Background: The radiolabeled amino acid O-(2-18F-ﬂuoroethyl)-L-tyrosine (FET) and thymidine analogue
3′-deoxy-3′-18F-ﬂuorothymidine (FLT) are widely used for positron emission tomography (PET) brain
tumor imaging; however, comparative studies are scarce. The aim of this study therefore was to compare FLT
and FET PET for the assessment of anti-VEGF response in glioblastoma xenografts.
Methods:Xenograftswith conﬁrmed intracranial glioblastomawere treatedwith anti-VEGF therapy (B20-4.1) or
saline as control. Weekly bioluminescence imaging (BLI), FLT and FET PET/CT were used to follow treatment
response. Tracer uptake of FLT and FET was quantiﬁed using maximum standardized uptake (SUVmax) values
and tumor-to-background ratios (TBRs). Survival, the Ki67 proliferation index and micro-vessel density
(MVD) were evaluated.
Results: In contrast to FLT TBRs, FET TBRs were signiﬁcantly lower as early as one week after treatment initiation
in the anti-VEGF group as compared to the control group. Following two weeks of treatment, both FLT and FET
TBRs were signiﬁcantly lower in the anti-VEGF group. In contrast, no signiﬁcant difference between the
treatment groups was detected using BLI. Furthermore, we found a signiﬁcantly lower MVD in the anti-VEGF
group as compared to the control group. However, we found no difference in the Ki67 proliferation index or
mean survival time.
Conclusion: FET appears to be a more sensitive tracer than FLT to measure early response to anti-VEGF therapy
with PET.
Advances in knowledge and implications for patient care FET PET appears to be an early predictor of anti-VEGF
efﬁcacy. Conﬁrmation of these results in clinical studies is needed.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Imaging of gliomas is a challenge and there are difﬁculties in
assessing true tumor response by conventional magnetic resonance
imaging (MRI) [1]. Accordingly, new functional imaging techniques
are increasingly used to obtain additional information about glioma
growth and response to therapy. Positron emission tomography (PET)
plays an important role in the management of cancer patients
and the majority of PET scans are performed with the glucose analogue
2′-deoxy-2′-18F-ﬂuoro-D-glucose (18F-FDG) [2]. In cancer cells, the in-
creased 18F-FDGuptake is caused by increasedmetabolism and a highering, University of Copenhagen,
.dk (M.K. Nedergaard).
. This is an open access article underexpression of the glucose transporters as compared to normal cells [3].
However, in normal brain tissue a high rate of glucosemetabolism is ob-
served. As such, a low tumor-to-background ratio (TBR) decreases the
sensitivity of FDG, and uptake of glucose in inﬂammatory cells compro-
mises the speciﬁcity of FDG in the brain [4]. PET with radiolabeled
amino acids like O-(2-18F-ﬂuoroethyl)-L-tyrosine (FET) and the
radiolabeled thymidine analogue 3′-deoxy-3′-18F-ﬂuorothimidine
(FLT) overcomes some of these limitations of FDG PET [5,6]. A low up-
take in normal brain tissue in combination with intense accumulation
in tumor cells is usually observedwith both FLT and FET. A variety of dif-
ferent PET tracers have been developed and investigated for brain
tumor imaging including PET tracers for imaging of integrin expression
and angiogenesis (e.g., 18F-Galacato-RGD [7] or 68Ga-NODAGA-RGD
[8,9]) and PET tracers for imaging of hypoxia (e.g., 18F-ﬂuromisodazole)
[10]. However, FLT and FET are among themost developed and promis-
ing PET tracers for brain tumor imaging [4]. Recently, the value of FLTthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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volume [12] in patients with glioma was evaluated. Due to the limited
transport of FLT across the intact blood–brain barrier (BBB) the sensitiv-
ity of FET PET was higher as compared to FLT PET. However, to our
knowledge other comparative studies between FLT PET and FET PET
have not been performed in clinical or preclinical studies.
Bevacizumab is a humanized monoclonal anti-VEGF antibody
which is used increasingly in patients with recurrent glioma [13].
Bevacizumab treatment causes normalization of the tumor vasculature,
a restored BBB and anti-tumor effect [14], which due to the limited
transport of FLT across the intact BBB, potentially has a more pro-
nounced inﬂuence on the accumulation of FLT as compared to the accu-
mulation of FET in brain tumors. The purpose of this studywas therefore
to evaluate the value of FET PET for anti-angiogenic response assess-
ment in an orthotopic xenograft model of human glioblastoma and
compare it with the value of FLT PET.
2. Materials and methods
2.1. Ethics statement
Animal care and all experimental procedureswere performed under
the approval of the Danish Animal Welfare Council (2013–15-2934-
00,064). Animal surgery and euthanasia using decapitation were per-
formed under Hypnorm/Midazolam anesthesia, and all efforts were
made to minimize animal suffering.
2.2. Establishment of the orthotopic glioblastoma model
The neurosphere glioblastoma cell culture NGBM_CPH048p6 [15]
was stably transfected with a lentiviral vector for expression of Fluc-
mCherry. Brieﬂy, HEK293T cells were grown to 60% conﬂuence and
3 μg of lentiviral constructs with Lipofectamine 2000was used to gener-
ate viral supernatants (in accordancewithmanufacturer's instructions).
The lentiviral supernatant and 4 μg/ml polybrene (Millipore, Watford,
UK) were used to infect NGBM_CPH048p6. Stability of the expression
was conﬁrmed with repeated measures of the bioluminescent signal
over a month in culture and 3 months in vivo.
Sixweeks oldNMRI (NavalMedical Research Institute) nude femalemice
were acquired from Taconic Europe (Lille Skensved, Denmark). Following
one to two weeks of acclimation ten μl cell suspension (100,000 cells) of
NGBM_CHP048p6_LUC neurosphere cells was injected intracranially using a
stereotactic frame, a micro drill and automated microinjection, as we have
described previously [16]. Neurosphere cells were injected 1.5 mm right of
the sutura saggitalis, 0.5 mm posterior to the bregma at a depth of 2–2.5 mm.Fig. 1. Experimental design The ﬁgure is a schematic illustration and timeline of the experiment
was performedweekly to determine established tumors (designated “tumor take” or TT). Herea
tion with FLT and FET PET was performed weekly on three consecutive days to monitor tumo
treatment at the different types of scans, days 1–29 are marked on the timeline. All scans perfo2.3. Experimental design
Fig. 1 shows a schematic viewof the experimental design.Micewere
injected with NGBM_CPH048p6_LUC neurosphere cells and tumor
growth was monitored by weekly bioluminescence imaging (BLI). FLT
and FET small animal PET in combination with computed tomography
(CT) scanningwas performedwhen the BLI signal indicated established
tumors by reaching a total ﬂux of 500,000 p/s/cm2/sr. An FET TBR above
1.6 on the following FET PET conﬁrmed tumor establishment (referred
to as “tumor take”). If the FET TBRwas below 1.6, treatmentwas initiat-
ed one week later to ensure “tumor take”. The FET PET at “tumor take”
was deﬁned as the baseline FET PET. The BLI scan performed two
days before and the FLT PET performed one day before the baseline
FET PET were also regarded as baseline scans. Mice were subsequently
divided in two groups, matched according to FET TBR and time
to “tumor take”, and included in the treatment study. B20-4.1
intraperitoneally (i.p.), (5 mg/kg) or 0.9% saline solution i.p. (control)
was administered twice weekly. Treatment was initiated one day after
the baseline FET PET. B20-4.1 is an antibody with afﬁnity for both the
human and the murine vascular endothelial growth factor A (VEGF-A)
[17]. Anti-cancer activity of B20-4.1 in several xenograft tumors has
previously been reported and the treatment regimen (5 mg/kg twice
weekly) was based on these studies [18,19]. B20-4.1 was kindly
provided by Roche (pRED oncology). The treatment response was
monitored by BLI, FLT and FET small animal PET/CT performed on
three consecutive days one and two weeks after treatment initiation.
Mice were daily monitored and sacriﬁced according to a predeﬁned
assessment score using humane endpoints as we have previously
described [20]. Subsequently, the brains were used for immunohisto-
chemistry (IHC).2.4. Bioluminescence imaging
Groups of threemicewere injected i.p. with 150mg/kgD-luciferin in
phosphate-buffered saline (Perkin Elmer, USA). Subsequently, mice
were anesthetized using 2% isoﬂurane and placed in the IVIS Lumina
XR optical imaging system (Caliper Life Sciences, Perkin Elmer, USA),
approximately 5 min after D-luciferin injection. Imaging parameters,
like ﬁeld of view and F-stop, were kept constant and acquisition time
was adjusted to optimize the signal without saturating the image. Scan-
ning was continued until the peak signal was captured for each mouse.
The Living Image 4.3.2 software on the IVIS system was used for image
analysis. A two-dimensional region of interest (ROI) at a ﬁxed size
was manually drawn covering the skull of the mouse and total photon
ﬂux was measured.al design starting with intracranial injection of tumor cells. Bioluminescence imaging (BLI)
fter B20 or control treatmentwas initiated (wide arrows). At “tumor take”, BLI in conjunc-
r development in response to treatment (slim arrows). To demonstrate the timing of the
rmed immediately before treatment initiations are referred to as baseline scans.
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FET and FLT were synthesized as previously described [16,21]. Mice
were anesthetizedwith Hypnorm/Midazolam (1ml/100 g bodyweight)
and kept on a heat-pad to prevent hypothermia. 8.1±0.18MBq 18F-FET
or 7.8 ± 0.13MBq FLTwas injected intravenously (i.v) in the tail vein of
the mice. A 10 min static PET image was obtained 20–30 min after FET
injection and 60–70 min after FLT injection using a MicroPET
Focus 120 (Siemens Medical Solutions, Malvern, PA, USA). PET
acquisition and image analysis were performed as previously
described [16]. In brief, the energy window for the emission scan
was set to 350–650 keV with a time resolution of 6 ns. PET data were
post-processed into sinograms and subsequently reconstructed
with the maximum a posteriori (MAP) reconstruction algorithm.
The quantiﬁcation unit was provided in Bq/ml. The intrinsic PET
resolution was 1.2 mm full-width at half-maximum and the voxel size
was 0.3 × 0.3 × 0.8 mm3. Scatter and attenuation correction were not
applied. The Inveon software (Siemens Medical Solutions) was used
for co-registration of small animal PET and CT images. At the location
of maximum tracer uptake in the tumor a 3D spherical ROI was placed
(ROIT). In the contralateral normal hemisphere a 4 mm3 spherical ROI
was drawn (ROIB). In the tumor region, SUVmax was calculated from
the voxel with the highest tracer concentration. In the normal hemi-
sphere, background activity was calculated as SUVmean. Tracer uptake
was expressed as a tumor-to-background ratio (TRR) using SUVmax of
the tumor and SUVmean of the background. Treatment responsewas cal-
culated as the difference in mean TBR after one and two weeks of treat-
ment. The 3D tumor volume containing all voxels with SUVmax values
≥75% of the tumor SUVmax was used to visualize the distribution of
FLT and FET in the brain tumor in Fig. 3.
2.6. Immunohistochemistry
Intact brains were removed from sacriﬁced mice and ﬁxed in 4%
paraformaldehyde for 24–48 h at 4 °C followed by incubation in 70%
ethanol. After ﬁxation brains were divided in two by coronal cutting in
the incision site. IHC was performed on formalin-ﬁxed, parafﬁn-
embedded tissue and histological sections (4 μm)were stainedwith he-
matoxylin and eosin (HE) for normal histological evaluation and withFig. 2. FLT and FET small animal PET/CT images of glioblastoma xenografts Fused FLT (top) and
(week−1) at baseline and after one week of treatment (week 1). Transverse views through th
0–1.5 SUVmax.antibodies detecting Ki67 and CD31. All IHC stainings were performed
manually and according tomanufacturer's instruction. Primary antibod-
ies used were CD31, a marker of endothelial cells (detecting both
human andmurine CD31, diluted 1:50, Abcam, UK) and Ki67, a marker
of cell proliferation (diluted 1:100, Abcam, UK). The Pannoramic MIDI
Slide scanner and the software Pannoramic Viewer 1.15.3 (3DHistech,
Hungary) were used for IHC analysis.
The micro-vessel density (MVD) was quantiﬁed using the CAIMAN
(Cancer Image Analysis: htpp://www.caiman.org.uk) online automatic
algorithm for endothelial cell segmentation [22]. Images with a known
size (approximately 2mm2) were captured at a magniﬁcation of ×10
from three to four regions of interest from each mouse. The majority
of the tumor from each slide was covered in the images. Images were
uploaded and the returned analyzed image ﬁle with the segmentation
overlaid was inspected and approved. MVD (micro-vessels/mm2)
of the specimen was estimated as a mean of MVD in the tree to four
analyzed regions.
The online available image analysis software ImmunoRatio [23] was
used for quantiﬁcation of the Ki67 proliferation index (percent of DAB-
staining area out of the total nuclear area). Depending on the tumor size
three to ten images were captured at themagniﬁcation of ×40 covering
the regions in which Ki67 staining was particularly prevalent (hot
spots). Camera settings and staining intensitywere evaluated according
to the web-application. The hematoxylin and DAB thresholds were
manually adjusted and results were interpreted with the pseudo-
colored images and the original image. The Ki67 proliferation index
was estimated as a mean of the Ki67 proliferation index in the three re-
gions with the highest Ki67 proliferation index.
2.7. Statistical analysis
Linear mixed models analysis and the SAS software (version 6.1 for
Windows; SAS Institute, Inc.) were used to compare the effect of treat-
ment at different time points in the FET, FLT and BLI scans. To make a
fair comparison between the treatment groups baseline values were
included as a covariate in the analysis. TBRs and BLI values were log-
transformed to obtain consistency with a Gaussian distribution.
GraphPad Prism version 6.05 for Windows (GraphPad Software Inc.,
USA)was used for Student's t-test, Pearson correlation analysis, SurvivalFET PET/CT (bottom) images showing tumor progression from the week before baseline
e brain of the same mouse with ROIT and ROIB illustrated. Scale bar applies to all images:
Fig. 3. Distribution of FLT and FET in glioblastoma xenografts The distribution of FLT (top row) and FET (bottom row) are demonstrated in the fused PET/CT images. Transverse views (1a,
1b, 2a, 2b) and coronal views (1c, 1d, 2c and 2d) through the brain of one representativemouse. The three-dimensional tumor volume containing all voxelswith SUVmax values ≥75% of the
tumor SUVmax is depicted in two dimensions for FLT (1b and 1d) and for FET (2b and 2d) for visual comparison of the tracer distribution.
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creation of graphs. All data were consistent with Gaussian distribution
when evaluated by the D'Agostino–Pearson normality test. Values are
expressed as mean± SEM (standard error of mean) if not stated other-
wise. P b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Tumor model characteristics
Nine mice were included in the B20-4.1 group and eight mice were
included in the control group. The mean time to “tumor take” (deﬁned
using PET) was 7± 0.3 weeks in the control group and 6.8± 0.4 weeksFig. 4. Correlation analysis of FLT and FET quantiﬁcations FLT and FET PET correlations of
all baseline scans (n= 14) quantiﬁed as A) SUVmax and B) TBRs using Pearson correlation
analysis. 95% CI is indicated by the broken lines.in the B20-4.1 group. Mean TBR at “tumor take” was 2.67 ± 0.3 in the
control group and 3.16 ± 0.3 in the B20-4.1 group. Mice were included
in the analysis if there was a baseline FET or FLT PET to conﬁrm “tumor
take”. As such, some of the mice did not have two evaluation scans due
to technical issues or due to tumor-related symptoms and euthanasia of
the mice before the second scanning week. The speciﬁc data included
for each mouse are shown in Additional File 1.
3.2. FET and FLT PET imaging of glioblastoma xenografts
Representative small animal FLT and FET PET/CT images of an
orthotopic NGBM_CPH048p6_LUC tumor from a single mouse are
shown in Fig. 2 for visual comparison. ROIT and ROIB are illustrated in
the ﬁgure. The FLT PET images show FLT uptake in the tumor and a
very low background uptake. A small increase in FLT uptake is observed
everyweek. In the FET PET images the FET uptake in the tumor is higher
at baseline and week 1 as compared to FLT uptake in the FLT PET im-
ages; however, the background activity is also higher leading to higher
TBR in the FLT images compared to the FET PET images. In Fig. 3, the dis-
tribution of FLT and FET in the brain tumor of a representative mouse is
illustrated. Although the tracer distribution of FET and FLT overlaps to
some degree, the distribution also differs in some regions of the
tumor. In order to compare the absolute SUVmax values and absolute
TBRs of FLT and FET, we performed Pearson correlation analysis and in-
cluded all baseline scans in the analysis. Strong positive correlations of
FLT and FET SUVmax values (r= 0.72, p = 0.001, n = 14) and no corre-
lation between FLT and FET TBRs (r=0.14, p=0.63, n=14) are shown
(Fig. 4A, B). In addition, we compared absolute SUVmax values and TBRs
in the FLT images with that of the FET images using Student's t-test.
Mean FLT SUVmax was signiﬁcantly lower than mean FET SUVmax
(1 ± 0.1 vs. 1.4 ± 0.1, n = 14; p = 0.002) (Fig. 5A). Furthermore, we
found a signiﬁcantly higher mean FLT TBR as compared to the mean
FET TBR (6.0 ± 0.6 vs. 2.7 ± 0.2; n = 14; p = 0.0005) (Fig. 5B).
3.3. FLT and FET PET imaging to detect anti-VEGF response in
glioblastoma xenografts
In order to investigate if FLT and FET small animal PET/CT could be
used to detect a response towards B20-4.1, we quantiﬁed the tracer up-
take using TBRs. In Fig. 6A and B, mean TBRs of FLT and FET are plotted
versus time after “tumor take” in the two groups. Using linear mixed
models for analysis of FLT scans, we found no signiﬁcant change in the
Fig. 5. Comparison of FLT and FET quantiﬁcations Comparisons (Student's t-test) of base-
line FLT and FET scans using A)Absolute SUVmax values and B) TBRs.Mean values±95% CI
are indicated in the ﬁgure **p b 0.01, ***p b 0.001.
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after one week of treatment (1.54; 95% CI (0.88–2.72); p = 0.12).
However, after two weeks of treatment, we found a signiﬁcantly
lower relative TBR of the treatment group as compared to the controlFig. 6. FLT and FET PET to monitor treatment response Quantiﬁcation of FET and FLT TBRs and a
TBRs. B) FET TBRs. C) FLT SUVmax. D) FET SUVmax. Mean values ± SEM in the control group (ngroup (0.43; 95% CI (0.89–0.85); p = 0.03) (Fig. 6A). In contrast,
when we quantiﬁed the FET uptake, we found a signiﬁcantly lower rela-
tive TBRof the treatment group as compared to the control group already
after one week of treatment (0.77; 95% CI (0.63–0.93); p = 0.01) and in
addition, a signiﬁcantly lower mean TBR in the treatment group after
two weeks of treatment (0.64; 95% CI (0.49–0.84); p = 0.005) (Fig. 6B).
As we found a signiﬁcant difference in FLT and FET TBR in response
to treatment, we also wanted to evaluate if we were able to detect a re-
sponse to treatment using absolute SUVmax values. In Fig. 6C and D,
mean absolute SUVmax values of FLT and FET are plotted versus time
after “tumor take” in the two treatment groups.
Analyzing FLT scans, we found no signiﬁcant difference in absolute
SUVmax values of the treatment group as compared to the control
group either after one week of treatment (−0.27; 95% CI (−0.57 to
0.03); p = 0.08) or after two weeks of treatment (−0.19; 95% CI
(−0.68 – 0.31); p = 0.42), (Fig. 6C). In line with the FLT scans, but in
contrast to FET scans using TBRs, we found no signiﬁcant difference in
absolute SUVmax values of the treatment group as compared to the con-
trol group either after one week of treatment (−0.15; 95% CI (−0.45 –
0.15); p=0.28) or after twoweeks of treatment (−0.3; 95% CI (−0.92 –
0.33); p = 0.29) (Fig. 6D).3.4. Bioluminescence imaging of glioblastoma xenografts
As we detected a difference in both FLT and FET TBRs in response to
treatment, we wanted to evaluate if there was a similar response using
BLI, where total ﬂux is a measure of viable tumor cell. Fig. 7A shows BLI
images of a representative xenograft mouse from the B20-4.1 and from
the control group for visual comparison. In Fig. 7B the mean total ﬂux
between the treatment and the control group is illustrated at the differ-
ent evaluation time points. In contrast to the FET and FLT PET scans, we
foundno signiﬁcant change in the relative ﬂuxof the treatment group as
compared to the control group either after oneweek of treatment (1.71;bsolute SUVmax values versus time after “tumor take” in the two treatment groups. A) FLT
= 4–7) and in the B20-4.1 group (n = 5–8). *p b 0.05, **p b 0.01; ns: non-signiﬁcant.
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95% CI (0.54–3.67); p = 0.33) (Fig. 7B).3.5. Ki67 labeling index and micro-vessel density
To evaluate if the changes in the FET tumor uptake following B20-4.1
treatment correlated with effects on tumor cell proliferation and MVD,
we performed IHC on brains removed at the end of treatment. Fig. 8A
shows representative IHC pictures fromH&E, CD31 and Ki67 stained tis-
sue sections and results from quantiﬁcation of Ki67 andMVDare shown
in Fig. 8B and C.We found no difference in the Ki67 labeling index in the
treatment group as compared to the control group (18.9 ± 1, n = 7 vs.
19.8 ± 2; n= 6; p= 0.7) (Fig. 8B). In order to investigate if the therapy
resulted in changes in the tumor vasculature, we compared the MVD in
the treatment and the control groups. We found a signiﬁcantly lower
MVD in the B20-4.1 group as compared to the control group (66 ± 8%,
n = 8 vs. 100 ± 10% n = 7; p = 0.02) (Fig. 8C).3.6. Effect of B20-4.1 on survival of xenografts
Fig. 9 shows Kaplan–Meier survival curves. We did not observe any
difference in median survival in the B20-4.1 as compared to the control
group (21 vs. 19 days; p=0.34; Hazard Ratio=0.65, 95% CI (0.18–1.56).Fig. 7. Bioluminescence imaging tomonitor treatment response A) Representative images
of bioluminescence imaging at baseline and after one and two weeks of treatment
showing tumor progression in a B20-4.1 mouse and a control mouse. B) Quantiﬁcation
of mean (± SEM) total ﬂux in the control group (n = 6–8) and in the B20-4.1 group
(n = 9) one and two weeks after treatment showing no signiﬁcant differences between
the treatment groups.4. Discussion
The purpose of the present studywas tomake a direct comparison of
FLT and FET small animal PET and to evaluate the performance of the in-
dividual tracers for detection of anti-VEGF treatment response in
orthotopic glioblastoma xenografts. Several studies have evaluated the
performance of the individual tracers for response assessment
[5,6,24,25], but to our knowledge there are no published data from di-
rect comparison between the tracers for response assessment in glioma
patients or xenografts. In the present study, we report for the ﬁrst time
data from a comparative study between FLT and FET in orthotopic glio-
blastoma xenografts.
In line with the two comparative FLT/FET studies performed in glio-
ma patients (where the tracers’ potential for non-invasive grading [11]
and volume assessment were evaluated [12]), we found a very low
background uptake of FLT and higher TBRs of FLT as compared to FET
in xenografts. We found no correlation of FLT and FET using TBRs,
which is in line with Nowosielski et al. [8] but in contrast to Jeong and
collegues [11], where strong positive correlations can be calculated
from the presented data. In the present study, we also evaluated abso-
lute SUVmax values and demonstrated strong positive correlation be-
tween FLT and FET PET, which is in line with the data presented by
Jeong at collegues [11]. These data indicate that the FLT and FET uptake
kinetics in the glioblastoma tumor model used in the present study is
comparable to the FLT and FET kinetics observed in glioblastoma pa-
tients. Furthermore, we also found highly signiﬁcant differences be-
tween the absolute SUVmax values and TBRs of the two tracers, which
indicate that FLT and FET uptake is highly determined by some common
factors (like e.g., tumor cell proliferation or tumor blood ﬂow) but also
individual and tracer-speciﬁc factors determine thebrain and tumor up-
take of FLT and FET.
FLT is a thymidine analogue that reﬂects DNA synthesis, thus serving
as a surrogate marker of proliferation. Tumor accumulation of FLT in
tumor cells is inﬂuenced by several factors amongwhich, the thymidine
kinase 1 (TK1) activity is thought to be a key regulator. However, the
FLT uptake mechanisms are apparently not as simple as earlier predict-
ed [26]. FET is an amino acid analogue and accumulation of 18F-FET in
tumor cells is presumably linked to increased expression of the L-type
amino acid transporters (LATs) in cancer cells and in endothelial cells
of the BBB [27,28], although this has not been fully investigated.
In the present study, we performed FET small animal PET and found
a signiﬁcant difference in FET TBRs in response to anti-VEGF treatment
already after one week of treatment. However, we did not ﬁnd a differ-
ence in FLT TBRs until after twoweeks of treatment. We also performed
BLI but did not ﬁnd a signiﬁcant difference in photon ﬂux at any time
points; neither did we ﬁnd any effect of treatment on survival. In addi-
tion, we observed a decrease in MVD in the anti-VEGF group as com-
pared to the control group, but not a detectable decrease in the Ki67
proliferation index.
It is likely, that the changes in the tumor accumulation of FET ob-
served after one week of treatment in part reﬂect changes in the
tumor vasculature and/or tumor blood-pool and not tumor cell regres-
sion due to anti-VEGF treatment. This theory is supported by recently
published data where a highly signiﬁcant correlation between regional
cerebral blood ﬂow and FET TBRs was demonstrated in glioma patients
20–40 min after FET injection [27]. Other studies have demonstrated
anti-cancer activity and a survival beneﬁt of Bevacizumab in glioma xe-
nografts [14,29]. In the present study, we used a different glioblastoma
tumor model and initiated B20-4.1 in a different treatment schedule,
which could explain the lack of impact on the Ki67 labeling index or sur-
vival (Figs. 8 and 9). However, with respect to themechanism of action,
the reduction of theMVD is the ﬁrst end point of Bevacizumab therapy,
which should be followed by a therapeutic anti-proliferative effect in
the further course of the disease. Possibly, in the current study the ani-
mals died due to rapid tumor growth before the reduction of MVD was
able to reduce proliferative activity and impact BLI, Ki67 or survival
204 M.K. Nedergaard et al. / Nuclear Medicine and Biology 43 (2016) 198–205time. Hence, in the present study FET PET detects an effect of anti-VEGF
therapy earlier than FLT PET because MVD (and FET PET) is earlier affected
than the proliferative activity of the tumor. In support of this conclusion
is the difference in FLT uptake between the treatment groups after two
weeks of treatment, which indicates an anti-proliferative effect of anti-VEGF.
Others have demonstrated that Bevacizumab treatment reduces the
MVD in addition to a decrease in vessel permeability [14]. Due to thedif-
ferent BBB permeability of FLT and FET, we expected that FLT uptake
compared to FET uptake would be more affected by anti-VEGF induced
changes in the tumor vasculature; however, in the present study, we
could not conﬁrm this speculation. In contrast to our expectations, FET
PET was affected by anti-VEGF treatment at an earlier time point than
FLT PET. However, as we did not directly measure the BBB permeability
using MRI or other established methods (e.g., Evans blue staining), it is
unknown if the vessel permeability was changed in addition to the de-
creased MVD observed in the present study.
A possible bias to the presented results is the different time from tracer
injection toPETacquisition. Basedonprevious studies, FETPET imageswere
acquired 20–30 min after FET injection [30,31], whereas FLT PET images
were acquired 60–70min after FLT injection [21]. However, the correlation
between FET uptake and regional bloodﬂow in the tumor is strongest early
after tracer injection (0–5 min) and the FET contribution from the blood-
pool is presumably constant at later time-points [27]. In support of this con-
clusion, dynamic FET PET performed in orthotopic glioblastoma xenografts
demonstrated a plateau in the time–activity curve 20–90 min after FET in-
jection [16]. This indicates that the results presumablywouldhave been the
same if PET had been performed 60–70 min after FET injection.
Absolute SUVmax of FLT and FET scans were also evaluated in the
present study. Although there is a tendency towards a reduction in
both FLT and FET SUVmax values in response to therapy, no signiﬁcantFig. 8.Micro-vessel density and Ki67 proliferative index in xenograft tumors A) Representative
eration index in the control group (n = 7) and in the B20-4.1 group (n = 6; p = 0.69). C
Mean ± SEM.changes were observed at any time points. In order to be able to fully
interpret the discrepancy between the FLT and FET small animal PET
data observed in this study and in future studies, amore comprehensive
understanding and investigation of the transport and retention mecha-
nisms of FLT and FET is required.
5. Conclusion
In orthotopic glioblastoma xenografts FET PET appears to detect
response to anti-VEGF therapy earlier than FLT PET, although a predic-
tive value for survival could not be demonstrated for both tracers in
this tumormodel. Further investigations are necessary to fully interpret
the discrepancy between the FLT and FET PET data.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nucmedbio.2015.12.002.
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